| Literature DB >> 11925283 |
Maurice Dysken1, Michael Kuskowski, Susan Love.
Abstract
The authors performed a multicenter, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of ondansetron (20 microg/day and 100 microg/ day) in treating cognitive decline in 185 patients with Alzheimer disease. Although ondansetron was well tolerated without any serious drug-related side effects, the study failed to demonstrate any significant cognitive improvement.Entities:
Mesh：
Substances：
Year: 2002 PMID： 11925283
Source DB: PubMed Journal: Am J Geriatr Psychiatry ISSN： 1064-7481 Impact factor: 4.105